Jiangsu CoWin Biotech Co., Ltd. (SHA:688426)
China · Delayed Price · Currency is CNY 27.39
+0.38 (1.41%)
At close: Jan 19, 2026
Jiangsu CoWin Biotech Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
Net Income | -137.72 | -157.21 | -84.41 | 159.26 | 125.85 | 108.16 | Upgrade |
Depreciation & Amortization | 38.83 | 38.83 | 33.55 | 23.25 | 15.73 | 4.6 | Upgrade |
Other Amortization | 4.33 | 4.33 | 3.69 | 3.06 | 2.31 | 1.66 | Upgrade |
Loss (Gain) From Sale of Assets | -0.19 | -0.19 | -1.24 | 0.51 | -1.29 | - | Upgrade |
Asset Writedown & Restructuring Costs | 3.44 | 3.44 | 4.27 | 0.06 | 0.03 | 0.03 | Upgrade |
Loss (Gain) From Sale of Investments | -18.21 | -18.21 | -26.71 | -7.94 | -7.57 | -3.27 | Upgrade |
Provision & Write-off of Bad Debts | 21.67 | 21.67 | 20.8 | 9.51 | 1.6 | 0.77 | Upgrade |
Other Operating Activities | 5.34 | 3.83 | 8.94 | 16.85 | 3.13 | 0.14 | Upgrade |
Change in Accounts Receivable | -11.84 | -11.84 | 52.74 | -97.15 | -16.08 | -19.67 | Upgrade |
Change in Inventory | -19.48 | -19.48 | 17.55 | -23.29 | -9.6 | -6.07 | Upgrade |
Change in Accounts Payable | 21.91 | 21.91 | -43.75 | 14.18 | 20.47 | 17.83 | Upgrade |
Change in Other Net Operating Assets | 2.9 | 2.9 | 16.33 | 13.15 | 8.43 | 2.59 | Upgrade |
Operating Cash Flow | -92.26 | -113.26 | -11.72 | 107.37 | 144.5 | 108.89 | Upgrade |
Operating Cash Flow Growth | - | - | - | -25.70% | 32.70% | 4570.17% | Upgrade |
Capital Expenditures | -36.28 | -48.41 | -159.22 | -100.38 | -124.39 | -13.46 | Upgrade |
Sale of Property, Plant & Equipment | 0.37 | 0.2 | 1.01 | 0.01 | 0.08 | - | Upgrade |
Cash Acquisitions | -13.83 | -13.83 | - | -5.21 | - | - | Upgrade |
Investment in Securities | 47.36 | 121.31 | -479 | -165 | 68.6 | -302.95 | Upgrade |
Other Investing Activities | 17.69 | 14.89 | 16.29 | 6.77 | 8.71 | 1.8 | Upgrade |
Investing Cash Flow | 15.31 | 74.16 | -620.91 | -263.81 | -47 | -314.6 | Upgrade |
Long-Term Debt Issued | - | 6 | - | - | - | 52.01 | Upgrade |
Long-Term Debt Repaid | - | -14.4 | -7.57 | -5.31 | -4.54 | -52.01 | Upgrade |
Net Debt Issued (Repaid) | -4.4 | -8.4 | -7.57 | -5.31 | -4.54 | - | Upgrade |
Issuance of Common Stock | - | 3.06 | - | 1,083 | - | 275 | Upgrade |
Repurchase of Common Stock | -43.66 | -43.66 | - | - | - | - | Upgrade |
Common Dividends Paid | -4.09 | -3.9 | -50.73 | - | - | -32.58 | Upgrade |
Other Financing Activities | 40.31 | - | 6 | -19.27 | -3.22 | -0.91 | Upgrade |
Financing Cash Flow | -11.83 | -52.9 | -52.3 | 1,058 | -7.76 | 241.52 | Upgrade |
Foreign Exchange Rate Adjustments | 0.17 | 0.21 | 0.64 | 1.79 | -0.77 | -0.9 | Upgrade |
Net Cash Flow | -88.61 | -91.79 | -684.29 | 903.72 | 88.98 | 34.91 | Upgrade |
Free Cash Flow | -128.54 | -161.67 | -170.94 | 6.99 | 20.11 | 95.44 | Upgrade |
Free Cash Flow Growth | - | - | - | -65.25% | -78.93% | - | Upgrade |
Free Cash Flow Margin | -76.89% | -128.44% | -99.77% | 1.34% | 5.94% | 40.92% | Upgrade |
Free Cash Flow Per Share | -1.16 | -1.45 | -1.52 | 0.07 | 0.24 | 1.36 | Upgrade |
Cash Income Tax Paid | 3.99 | 5.66 | 23.45 | 36.72 | 17.62 | 20.34 | Upgrade |
Levered Free Cash Flow | -320.01 | -127.04 | -115.19 | -38.17 | -9.99 | 56.26 | Upgrade |
Unlevered Free Cash Flow | -319.33 | -126.16 | -114.13 | -36.96 | -8.79 | 56.33 | Upgrade |
Change in Working Capital | -9.75 | -9.75 | 29.39 | -97.19 | 4.71 | -3.19 | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.